Background/Aims: Lipocalin 2 (LCN2), an important mediator of a variety of cellular processes, is involved in regulating the inflammatory response, but its roles in different inflammatory diseases are controversial. Because the role of LCN2 in ocular inflammation has been unclear until now, we explored the function of LCN2 in lipopolysaccharide (LPS)-induced ocular inflammation in vivo and in vitro. Methods: Endotoxin-induced uveitis (EIU) was induced in male Sprague Dawley rats by the intravitreal injection of LPS. The expression and location of LCN2 in the retina were detected with western blotting and immunohistochemistry, respectively. We determined the clinical scores for anterior inflammation, quantified the infiltrated inflammatory cells, and measured the pro-inflammatory factors to determine the anti-inflammatory effects of LCN2 in EIU eyes. Cultured primary rat Müller cells were stimulated with LPS and the expression and secretion of LCN2 were measured with real-time PCR, western blotting, and an ELISA. After Müller cells were cotreated with LPS and LCN2 or PBS, the expression and secretion of TNF-α, IL-6, and MCP-1 were examined with realtime PCR, western blotting, and ELISAs. Western blotting and immunofluorescence were used to detect the phosphorylation and cellular distribution of nuclear factor kappaB (NF-κB) subunit p65. Results: In EIU, the expression of LCN2 was significantly upregulated in the retina, especially in the outer nuclear layer (mainly composed of Müller cells). LPS stimulation of cultured Müller cells also markedly elevated LCN2 expression. Intravitreal injection of LCN2 significantly reduced the clinical scores, inflammatory infiltration, and protein leakage in EIU, which correlated with the reduced levels of proinflammatory factors in the aqueous humor
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Introduction
Uveitis, a common ocular inflammatory disease, leads to 5%-10% visual impairment in the world [1] . It is not only triggered by infectious agents, such as bacteria and viruses, but also manifests as part of systemic immune diseases, such as juvenile idiopathic arthritis and Behçet's disease [2] . The inflammation can compromise both the anterior and posterior segments of the eye. Endotoxin-induced uveitis (EIU) is an animal model widely used to study acute ocular inflammation, including uveitis, and can be established by the systemic or topical application of lipopolysaccharide (LPS), a component of the Gram-negative bacterial outer membrane [3, 4] . During uveitis, the blood-ocular barrier (BOB) can be disrupted and inflammatory cells, such as macrophages and neutrophils, infiltrate the eye [5, 6] . Inflammatory mediators, such as tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), and monocyte chemoattractant protein 1 (MCP-1) also participate in the pathogenesis of EIU [7, 8] . Anti-inflammatory agents, including corticosteroids and immunosuppressants, are often used in the treatment of uveitis to control inflammation and prevent relapse [9] . However, the long-term use of these drugs can induce various adverse reactions, including glaucoma, cataract, and increased susceptibility to infection [10] . Therefore, the search for novel regulatory factors involved in the progression of EIU is essential to the development of appropriate therapeutic strategies.
Lipocalin 2 (LCN2), a secretory glycoprotein, belongs to the lipocalin family, the members of which bind various hydrophobic molecules, including retinoids, steroids, and fatty acids [11] . LCN2 was first identified as a bacteriostatic factor, and recent evidence has identified its roles in diverse cellular processes, including cell survival and death, migration, and morphology [12, 13] . LCN2 is also reported to be an acute phase protein and its expression is induced in many organs in response to injury or inflammatory stimuli [14, 15] . However, conflicting roles for LCN2 in different inflammatory diseases have been reported. Several in vivo studies reported that LCN2 drives the inflammatory responses in pneumonia, psoriasis, and Alzheimer's disease [16] [17] [18] , whereas other studies have demonstrated that LCN2 exerts an anti-inflammatory activity in sepsis, tuberculosis, and autoimmune encephalomyelitis [19] [20] [21] . However, there have been few studies of the role of LCN2 in ocular diseases, especially uveitis.
We undertook this study to investigate the effects of LCN2 in LPS-induced ocular inflammatory models and the regulatory mechanisms involved. Our results show that LCN2 is upregulated in the retina and Müller cells in EIU and acts as an endogenous antiinflammatory mediator. LCN2 not only ameliorated the inflammatory manifestation in vivo but also reduced the release of inflammatory mediators in Müller cells in vitro, at least in part by inhibiting the activation of the NF-κB signaling pathway. These data together suggest that LCN2 is a potential therapeutic agent for the treatment of acute ocular inflammation, including uveitis.
Materials and Methods

Animals
All protocols were approved by the Animal Ethics Committee of the Eye and Ear Nose Throat Hospital of Fudan University, China, and were performed in accordance with the statement of ARVO on the Use of
Histopathological evaluation
The enucleated eyes were fixed in 4% paraformaldehyde for 24 h at room temperature, and then stored in 70% alcohol at 4 °C until embedded in paraffin. Serial sagittal sections (5 μm thick) were cut through the optic nerve head and stained with hematoxylin and eosin (H&E). The anterior chamber, iris-ciliary body, vitreous, and retina were examined with light microscopy (Leica Microsystems, Wetzlar, Hesse-Darmstadt, Germany). Only one section of each eye was chosen, and each group contained three eyes. Infiltrating cells were counted by an investigator blinded to the treatment group.
Immunohistochemistry
The corneas and lenses of the enucleated eyes were removed, and the remaining eye cups were fixed in 4% paraformaldehyde at 4 °C overnight. The eye cups were dehydrated in 20%-30% graded sucrose, embedded in optimal cutting temperature (OCT) compound (Tissue-Tek; Tokyo, Japan), and cryosectioned to sagittal sections (10 μm thick). The sections were incubated with 5% goat serum and 0.3% Triton X-100 in PBS for 1 h at room temperature, and were then incubated overnight at 4 °C with a mixture of primary antibodies: rabbit anti-LCN2 antibody (ab63929, diluted 1:100, Abcam, Cambridge, UK) and mouse antiglutamate synthase (anti-GS) antibody (ab64613, diluted 1:100, Abcam). After the sections were washed with PBS, they were incubated with a mixture of the corresponding secondary antibodies (A-11008, A-21422, diluted 1:1000, Invitrogen, Garlsbad, CA, USA) for 1 h at room temperature. The sections were rinsed with PBS, counterstained with 4',6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) for 5 min, and examined with a laser confocal microscope (Leica Microsystems). Table 2 . Primer sequences used for real-time PCR in this study [22] . Briefly, the retinas of 20 rats were collected by microdissection under sterile conditions and digested with 0.25% trypsin for 5 min. After the trypsin was deactivated and the samples centrifuged at 500 ×g for 5 min, the cell pellets were resuspended in Dulbecco's modified Eagle's medium/nutrient mixture F-12 (Gibco, New York, NY, USA) supplemented with 20% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (SigmaAldrich), plated in 75 cm2 culture flasks, and incubated at 37 °C in a humidified atmosphere containing 5% CO2. Cells from passages 2-4 were used for the experiments. LPS or LCN2 was first dissolved in PBS (1 mg/ ml) and diluted with culture medium to 0.01, 0.1, and 1 μg/ml or to 0.5, 1, and 2 μg/ml, respectively. The Müller cells were cultured in six-well plates and then simultaneously stimulated with LPS and/or LCN2 at the indicated concentrations for the indicated times. Equal amounts of PBS were added to the culture medium as the controls. After stimulation, the cells and supernatants were harvested.
Immunocytofluorescence
Müller cells were seeded on coverslips in 24-well plates, and then simultaneously stimulated with 1 μg/ml LPS and/or 1 μg/ml LCN2 for 1 h. After stimulation, the cells were washed with PBS and then fixed with 4% paraformaldehyde for 15 min. After the cell membranes were permeabilized with 0.3% Triton X-100, they were blocked with 5% goat serum for 1 h at room temperature and then incubated overnight at 4 °C with the following primary antibodies: rabbit anti-GS antibody (ab49873, diluted 1:100; Abcam), rabbit anti-NF-κB p65 antibody (4764S, diluted 1:100; Cell Signaling Technology, Beverly, MA, USA), or rabbit anti-NF-κB phospho-p65 antibody (3033S, diluted 1:100; Cell Signaling Technology). The coverslips were then washed three times with PBS and incubated with the corresponding secondary antibodies (A-11008, A-21428, diluted 1:1000, Invitrogen) for 1 hour at room temperature. After three washes with PBS, the cells were counterstained with DAPI (Sigma-Aldrich) for 5 min. The coverslips were visualized and photographed with fluorescence microscopy (Leica Microsystems).
Western blotting
The retinal tissues or Müller cells were mixed with RIPA buffer (Beyotime), homogenized, incubated on ice for 30 min and centrifuged at 12, 000 ×g for 15 min at 4 °C. The nuclear proteins of Müller cells and retinal tissues were extracted using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, Rockford, IL, USA). The protein concentration in each sample was measured with a BCA Protein Assay Kit (Beyotime). An equal amount of protein (40 μg) from each sample was loaded onto a sodium dodecyl sulfate polyacrylamide gel and separated with electrophoresis, and transferred to polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). The membranes were blocked in 5% skim milk and then incubated overnight at 4 °C with the following primary antibodies: rabbit anti-LCN2 (ab63929, diluted 1:400; Abcam), rabbit anti-glial fibrillary acidic protein (ab68428, anti-GFAP; diluted 1:1000; Abcam), rabbit anti-TNF-α (ab6671, diluted 1:500; Abcam), rabbit anti-IL-6 (21865-1-AP, diluted 1:300; Proteintech), rabbit anti-MCP-1 (ab25124, diluted 1:2000; Abcam), rabbit anti-NF-κB p65 (4764S, diluted 1:1000; Cell Signaling Technology), rabbit anti-NF-κB phospho-p65 (Ser536) (3033S, diluted 1:1000; Cell Signaling Technology), mouse anti-β-actin (ab6276, diluted 1:1000; Abcam), rabbit anti-H3 (4499S, diluted 1:1000; Cell Signaling Technology), or rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (10494-1-AP, anti-GAPDH; diluted 1:1000; Proteintech). The membranes were incubated with the corresponding horseradish-peroxidaseconjugated secondary antibodies (SA00001-2, SA00001-1, diluted 1:5000, Proteintech) for 1 h at room temperature. The blots were developed with Pierce ECL Western Blotting Substrate (Thermo Scientific), and analyzed with the Kodak Digital Imaging System (Kodak, Rochester, NY, USA).
Real-time PCR
Total RNA was extracted from Müller cells with TRIzol Reagent (Invitrogen), according to the manufacturer's instructions. The PCR primers were synthesized by Tsingke Biological Technology (Shanghai, China) based on the mRNA sequences published in the National Center for Biotechnology Information database, and are listed in Table 2 . Complementary DNA (cDNA) was generated with the PrimeScript RT reagent Kit (Takara, Shiga, Japan). reverse primer (100 μM) and 5.2 μL of nuclease-free water. The thermal cycling conditions were 95 °C for 10 min, followed by 40 cycles of 95 °C for 30 s and 60 °C for 30 s, and the melting curve profiles were generated at the end. The expression level of each mRNA was normalized to that of Gapdh mRNA and calculated with the 2 −ΔΔCt method.
Enzyme-linked immunosorbent assays (ELISAs)
The concentrations of LCN2 in cell culture media and those of TNF-α, IL-6, and MCP-1 in the AqH and cell culture media were quantified with the corresponding ELISA kits (Rat LCN2 ELISA Kit, ab119602; Rat TNF-α ELISA Kit, ab100785; Rat IL-6 ELISA Kit, ab100772; Rat MCP-1 ELISA Kit, ab100777; Abcam), according to the manufacturer's instructions.
Statistical analyses
The data were analyzed with the SPSS 21.0 software (Chicago, IL, USA). All values are expressed as the means ± SEM of at least three independent experiments. The statistical analysis was performed by comparing the means of different groups with Student's unpaired or paired two-tailed t test, or one-way ANOVA followed by Tukey's multiple-comparisons test. A P value < 0.05 was considered statistically significant.
Results
Expression of LCN2 is upregulated in the retina and Müller cells in EIU
EIU is a classical model for the study of acute ocular inflammation [3] . As shown in Fig. 1a , an intravitreal injection of 250 ng of LPS caused iris hyperemia, protein exudation, hypopyon, and miosed pupil in the anterior segment. H&E staining revealed marked inflammatory cell infiltration in the iris-ciliary body region and the posterior vitreous cavity 24 h after the intravitreal injection of LPS (Fig. 1b) , and the mRNA levels of TNF-α, a well-known marker of ocular inflammation [23] , were also significantly increased in the retina by LPS (Fig. 1c) . These results demonstrate that the EIU model was successfully established with the intravitreal injection of LPS.
To investigate whether LCN2 participates in regulating ocular inflammation, we first examined its expression in response to EIU. The expression of LCN2 was significantly elevated in the retina, one of the main tissues affected by uveitis [24] , from 8 h poststimulation (Fig. 1d) . To explore the cellular localization of LCN2 in the retina, double immunofluorescent staining for LCN2 and glutamate synthase (GS), a marker of Müller cells [25] , was performed 24 h after the intravitreal injection of LPS (Fig. 1e) . LCN2-positive cells also expressing GS were more obvious in the inner nuclear layer (INL) and ganglion cell layer (GCL) of the retinas in the LPS-treated eyes than in the PBS-treated eyes. The number of LCN2-positive Müller cells that were also positive for GS in the retinal sections increased significantly after LPS stimulation (Fig. 1f) . These findings indicate that LCN2 expression is upregulated in the retina and Müller cells in EIU, and that reactive Müller cells may be one of the major cellular sources of LCN2 in the retina.
Treatment with LCN2 protects against LPS-induced inflammation
We next investigated the specific role of LCN2 in EIU using an exogenous recombinant LCN2 protein. The inflammation in the anterior chambers of the different groups was assessed with biomicroscopy at different time points after LPS challenge. The clinical scores were evaluated blindly, according to a previously reported scoring system [4] (Table 1) . As shown in Fig. 2a , LPS injection induced clear inflammatory responses, such as iris hyperemia, protein exudation, and hypopyon, which peaked at 24 h and lasted for 72 h. However, the inflammatory reactions triggered by LPS were markedly alleviated by LCN2 treatment. At 24, 48, and 72 h after treatment, the clinical scores in the LPS+LCN2 group were significantly lower than those in the LPS+PBS group (LPS+LCN2 group vs LPS+PBS group at 24 h: 6.00 ± 0.24 vs 3.50 ± 0.32, respectively, P < 0.0001; at 48 h: 3.90 ± 0.19 vs 2.10 ± 0.43, respectively, p = 0.005; at 72 h: 2.40 ± 0.19 vs 1.60 ± 0.29, respectively, p = 0.0497; Fig. 2b ). These results suggest that LCN2 treatment reduces the clinical severity of EIU.
Because EIU is characterized by the breakdown of the BOB and inflammatory cell infiltration of the eyes, we examined the inflammatory cell infiltration with H&E staining. As shown in Fig. 2 , inflammatory cells were noticeably recruited into the eyes after LPS injection, especially at 24 h (Fig. 2c, 2d) . However, the LCN2-treated eyes showed a significant reduction in infiltrating cells in the iris-ciliary body region and the posterior vitreous cavity compared with the eyes without LCN2 treatment at 24, 48, and 72 h after LPS injection. It is noteworthy that there was a 69.14% reduction in inflammatory cells in the iris ciliary body region and a 74.23% reduction in the posterior vitreous cavity in the LCN2-treated eyes at 24 h after LPS injection (Fig. 2e, 2f ). These findings imply that LCN2 attenuates histopathological ocular inflammation. Because the LPS-induced inflammation in the anterior segment of the eye peaked at 24 h, we chose this time point to explore the protein concentration, cell numbers, and proinflammatory factor levels in the AqH. The injection of LPS substantially increased the protein concentration and inflammatory cells in the AqH, which were mitigated by LCN2 treatment (Fig. 3a,  3b) . We also determined the amounts of TNF-α, IL-6, and MCP-1 released into the AqH. These important proinflammatory factors were significantly increased in the iris-ciliary body during LPS-induced uveitis [26, 27] . As shown in Fig. 3c-3e , the concentrations of TNF-α, IL-6, and MCP-1 in the AqH were significantly elevated 24 h after EIU induction, whereas treatment with LCN2 markedly reduced their levels. A western blotting analysis demonstrated that LPS challenge significantly induced the expression of TNF-α, IL-6, and MCP-1 in the retina, which was clearly inhibited by LCN2 treatment at 24, 48, and 72 h after the intravitreal injection of LPS (Fig. 3f-3h) . These results suggest that LCN2 mitigates the inflammation in the anterior segment and posterior segment of the eye.
LCN2 expression is upregulated in LPStreated Müller cells
Müller cells, the major glial cells in the retina, play an important role in retinal inflammation [28] . LPS-induced inflammation paralleled the reactive gliosis of the retinal Müller cells, because the expression of the gliotic marker GFAP was upregulated in a time-dependent manner (Fig. 4a, 4b) . Furthermore, the expression of LCN2 was significantly upregulated by LPS in the outer nuclear layer of the retina, where Müller cells are one of the main cellular components [29] . Therefore, we investigated the effects of LCN2 on LPS-induced inflammation in Müller cells. The purity of the primary cultured Müller cells was confirmed by detecting the marker protein GS with immunocytochemical staining (Fig. 4c) . Upon LPS stimulation, the expression of GFAP in Müller cells increased markedly, in a dose-dependent manner (Fig. 4d) , demonstrating that LPS activated Müller cells in vitro. The Müller cells were then exposed to different concentrations of LPS (0, 0.01, 0.1, or 1 μg/ml) for 24 h, or to 1 μg/ml LPS for different time periods (0, 4, 8, 24 or 48 h). The protein and mRNA expression of LCN2 induced by LPS were upregulated in a dose-and timedependent manner (Fig. 5a-5d) . Similar results were obtained by measuring the LCN2 levels in the cell supernatant (Fig. 5e, 5f ). These data show that LPS induces the acute expression and secretion of LCN2 in Müller cells. 
LCN2 suppresses LPS-induced expression of proinflammatory cytokines in Müller cells
Various inflammatory cytokines and chemokines were significantly increased in Müller cells after LPS stimulation, among which TNF-α, IL-6, and MCP-1 were particularly obvious (Fig. 6a) . After treatment with different doses of LCN2 (0.5, 1, or 2 μg/ml), the LPS-induced expression of TNF-a, IL-6, and MCP-1 was suppressed in a dose-dependent manner at the protein level (Fig. 6b-6d ). LPS stimulation (1 μg/ml) also strongly induced the mRNA expression of TNF-α, IL-6, and MCP-1, and enhanced their secretion into the supernatant, and these processes were antagonized by 1 μg/ml LCN2 (Fig. 6e-6j) . These results indicate that LCN2 protects Müller cells against the inflammatory reactions induced by LPS.
LCN2 inhibits LPS-induced NF-κB p65 phosphorylation and nuclear translocation in Müller cells and retinal tissues
NF-κB is an important transcription factor that controls the expression of various genes involved in inflammation. Its activation, which is marked by the phosphorylation and nuclear translocation of the NF-κB subunit p65, increases the expression of many inflammatory cytokines and chemokines [30] . To determine the molecular mechanism were measured with ELISAs. Quantification of the band intensities after normalization to β-actin is presented. Gapdh was used as the internal control for real-time PCR. One-way ANOVA with Tukey's multiple-comparisons test was used. n = 3 for each group in A-D; n = 6 for each group in E-F. *P<0.05, **P<0.01. were used as the loading control for the nuclear fractions. GADPH was used to exclude the possibility of cross contamination. Quantification of the band intensities after normalization to H3 is presented. One-way ANOVA with Tukey's multiple-comparisons test was used. n = 3 for each group. *P<0.05, **P<0.01. of the LCN2-inhibited inflammatory reactions, we investigated whether the activation of NF-κB is negatively regulated by LCN2. Immunofluorescent images showed that LCN2 treatment significantly reduced the level of phospho-p65 in the nucleus and inhibited the nuclear translocation of p65 (Fig. 7a, 7b) . A western blotting analysis of the protein levels of phospho-p65 (at Ser536) in whole-cell lysates and the nuclear fraction of p65 confirmed the immunofluorescence results (Fig. 7c, 7d) . We also examined the effects of LCN2 on the activation of NF-κB p65 in lysed rat retina. Our results showed that up-regulation of phospo-p65 (at Ser536) and nuclear translocation of p65 induced by LPS were significantly mitigated by LCN2 treatment (Fig. 7e, 7f) , which is consistent with the findings from cultured Müller cells. These data suggest that LCN2 inhibits the inflammatory response induced by LPS by repressing the activation of the NF-κB signaling pathway.
Discussion
Uveitis is a prevalent health problem with potentially sight-threatening outcomes [2] . Commonly used anti-inflammatory drugs, such as corticosteroids, have many adverse effects [10] . Therefore, it is critical to develop more effective therapeutic strategies. In this study, we provide the first evidence that LCN2 is critically involved in acute retinal inflammation as an anti-inflammatory factor. Using a model of EIU, we found that although the expression of LCN2 was elevated in the retina and Müller cells, LCN2 treatment not only reduced the signs of anterior uveitis and lessened retinal damage in vivo, but also reduced the production of proinflammatory mediators, such as TNF-α, IL-6, and MCP-1, in Müller cells. LCN2 exerted its anti-inflammatory effects by negatively regulating the activation of the NF-κB pathway. These results indicate that LCN2 might be utilized as an anti-inflammatory mediator in the treatment of ocular inflammatory diseases.
An important finding of our study is that the expression of LCN2 increased after LPS stimulation and protected the ocular tissues against the inflammatory reactions induced. Previous studies have shown that after LPS stimulation, Lcn2 as an acute phase protein is rapidly induced in various cells of the central nervous system, including astrocytes, microglia and endothelial cells [31] [32] [33] . Moreover, the expression of LCN2 was found to be markedly elevated in the brain and in cultured astrocytes at 4-8 h after exposure to an inflammatory stimulus [19, 34, 35] . Similar to these studies, we found that LCN2 protein levels in retinal tissues and in cultured Müller cells were significantly increased at 8 h after LPS treatment, suggesting that LCN2 is likely to be involved in the early response to inflammatory stimuli. It is widely known that LCN2 plays various biological roles in cell survival, apoptosis and iron transport [36] . Previous studies have shown that LCN2 is an important mediator in the regulation of a range of inflammatory diseases, including sepsis, inflammatory bowel disease, and in inflammatory disorders of the central nervous system [19, 37, 38] . However, the specific roles of LCN2 in different inflammatory conditions are not always consistent. For example, Nam et al. found that LCN2 acted in a proinflammatory manner in experimental autoimmune encephalomyelitis models of neuroinflammation [39] , and Jang et al. reported that Lcn2 −/− mice had reduced brain IL-12, TNF-α, and IL-23 mRNA levels after LPS injection, suggesting a proinflammatory role LCN2 in the central nervous system [32] . In contrast, Kang et al. found that Lcn2 −/− mice treated with LPS had significantly elevated levels of proinflammatory cytokines and displayed worse behavioral performance than normal mice [19] . The anti-inflammatory actions of LCN2 are also supported by the finding of Zhang et al. that LCN2 reduced the LPS-induced expression of cytokines by RAW264.7 macrophages [40] . Until now, the specific function of LCN2 in uveitis has not been examined. In the present study, we provide the first evidence that LCN2, a positive acute phase protein, dampens ocular inflammatory reactions.
The ocular inflammation in EIU is characterized by a breakdown of BOB, with inflammatory cell infiltration affecting both the anterior and posterior segments of the eye [5, 6] . Consistent with this, clinical and histopathological evaluations demonstrated that LCN2 suppressed inflammatory infiltration into the eyes, indicating that it protects against the disruption of BOB in EIU. This is further supported by the finding that LCN2 inhibited the protein and cell leakage into the AqH caused by LPS. Previous studies have shown that TNF-α, IL-6, and MCP-1 are elevated in the AqH of patients with uveitis and in animal models of uveitis [41, 42] . TNF-α and IL-6 play key roles in initiating and perpetuating local immune responses [7] , and MCP-1 is an important mediator of monocyte infiltration [43] . Our results show that LCN2 reduced the contents of TNF-α, IL-6, and MCP-1 in both the AqH and the retina. It has previously been shown that infiltrated leukocytes are the main cellular sources of TNF-α, IL-6, and MCP-1 in ocular inflammation [44] . Therefore, the reduced production of these proinflammatory factors in the AqH and retina may result from the attenuation of leukocyte infiltration. Taken together, these findings suggest that LCN2 inhibits the disruption of on BOB and leukocyte infiltration during the inflammatory processes induced by LPS in vivo.
Müller cells, the main macroglia in the retina, are reported to actively participate in the innate immunity of the retina, especially in infectious conditions [28] . Müller cells have also been identified as the decisive cells in the immune pathology of uveitis [45] . Studies of EIU in rats revealed short-term changes in the Müller cell physiology, indicating that Müller cells play a vital role in uveitis [46] . The gliosis of Müller cells is a well-established response to virtually every retinal disease, and its acute form is usually beneficial, because it tends to be conservative or nonproliferative [47] . Here, we confirmed the acute gliosis of Müller cells and the concomitant upregulation of LCN2 induced by stimulation with LPS in vivo and in vitro. We have also shown that LPS induces the mRNA and protein expression and secretion of TNF-a, IL-6, an MCP-1 in cultured primary Müller cells, whereas LCN2 treatment markedly inhibited their production. Therefore, LCN2 is probably an endogenous anti-inflammatory mediator that acts in an autocrine manner on Müller cells.
The transcription factor NF-κB plays a critical role in the inflammatory and immune responses [48] . In unstimulated cells, NF-κB is inactive in the cytoplasm. Once stimulated by endotoxins or pro-inflammatory mediators, NF-κB is phosphorylated and activated. The released p65 subunit then enters the nucleus, where it acts on specific sequences in the promoter regions of its target genes, such as TNFA, IL6, and MCP1 [49] [50] [51] . The activation of NF-κB by inflammatory stimuli can lead to a cytokine cascade reaction and the exacerbation of the inflammatory responses. Correspondingly, the downregulation of NF-κB activity contributes to the amelioration of inflammatory reactions, including in uveoretinitis [52] . In this study, we found that LCN2 significantly reduced the LPS-induced phosphorylation of p65 at Ser536, which has been shown to change the kinetics of p65 translocation [53] . As we expected, the LPS-induced nuclear translocation of p65 was also suppressed by LCN2. These results suggest that the inhibition of NF-κB activation might explain the anti-inflammatory effects of LCN2.
This study had some limitations. EIU resembles acute ocular inflammation, but uveitis can become recurrent or chronic. The role of LCN2 in chronic ocular inflammation remains unclear. A model of chronic human uveitis, such as experimental autoimmune uveoretinitis, is under investigation in our laboratory. Other signaling pathways that may be involved in the anti-inflammatory effects of LCN2 also require clarification.
Conclusion
In summary, we found that LPS strongly upregulated LCN2 in vivo and in vitro and that LCN2 alleviated ocular inflammation, confirming that LCN2 is a positive acute phase protein.
We also identified the possible anti-inflammatory mechanism of LCN2, which acts by suppressing the activation of NF-κB. Considering its small size and simple structure, LCN2 is a potential candidate agent for the treatment of ocular inflammatory diseases in the future.
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